Drug companies seek MS patients to lobby for new productsBMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7229.207/b (Published 22 January 2000) Cite this as: BMJ 2000;320:207
- Gavin Yamey
Schering Health Care, the manufacturer of the multiple sclerosis treatment Betaferon (interferon beta), is seeking the support of patients to lobby the National Institute for Clinical Excellence (NICE) before its ruling on the drug in May. The drug costs about £10000 ($16000) a year per patient, and many health authorities have been reluctant to …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial